Neuraxpharm has expanded outside of its European base by launching its first product in Japan. Having last year struck a deal with Takeda to acquire Buccolam (midazolam), Neuraxpharm has introduced the value-added product in Japan following its approval as “the first buccally administered formulation for the treatment of status epilepticus in the country.” (Also see "Neuraxpharm Buccolam Acquisition Opens Up Opportunities" - Generics Bulletin, 14 September, 2020.)
Referring to Japan as “the world’s second largest central nervous system market” and the third largest pharmaceutical market in the...
